This review characterizes the discrete evidence frameworks surrounding PCV chemotherapy and IDH inhibitors in the context of treating oligodendrogliomas, IDH-mutant 1p/19q codeleted gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.